Immunotherapy drug keytruda takes on mysterious cancers of unknown origin
Disease control
Completed
This phase 2 trial is investigating whether the immunotherapy drug pembrolizumab (Keytruda) can help people with a rare and aggressive cancer called carcinoma of unknown primary (CUP), where doctors cannot find where the cancer started. Participants have not received prior treatm…
Phase: PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC